AR036512A1 - COMPOSITION TO PREVENT OR TREAT HYPERLIPIDEMIA OR HYPERGLUCEMIA USE AND TREATMENT METHOD - Google Patents
COMPOSITION TO PREVENT OR TREAT HYPERLIPIDEMIA OR HYPERGLUCEMIA USE AND TREATMENT METHODInfo
- Publication number
- AR036512A1 AR036512A1 ARP020103462A ARP020103462A AR036512A1 AR 036512 A1 AR036512 A1 AR 036512A1 AR P020103462 A ARP020103462 A AR P020103462A AR P020103462 A ARP020103462 A AR P020103462A AR 036512 A1 AR036512 A1 AR 036512A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- salt
- appropriate substituent
- formula
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/717—Celluloses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/745—Polymers of hydrocarbons
- A61K31/75—Polymers of hydrocarbons of ethene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/755—Polymers containing halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/795—Polymers containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Reivindicación 1: Una composición para prevenir o tratar hiperlipidemia, hipercolesterolemia o hiperglucemia, que comprende un polímero o su sal, el cual se puede obtener por polimerización de un monómero de fórmula (1) o su sal en presencia de un iniciador de radicales, o por polimerización de un monómero de fórmula (1) o su sal con un monómero de fórmula (2) o su sal en una relación molar de (1):(2) de 1:0,1 a 1:25, en presencia de un iniciador de radicales, donde: R1 y R3 cada uno son átomo de hidrógeno o un grupo alquilo inferior; R2 y R4 cada uno son un grupo acilo, un grupo sililo alifático, un grupo aminoalquilo inferior que puede tener uno o más sustituyente(s) apropiado(s), un grupo heterocíclico que puede tener uno o más sustituyente(s) apropiado(s), o un grupo carboxi esterificado por el residuo de celulosa opcionalmente sustituido por uno o más alquilos inferiores y/o alquenoilos inferiores, como componente activo, asociado con un vehículo o excipiente no tóxico farmacéuticamente aceptable. Reivindicación 6: La composición de la reivindicación 5, donde el polímero o su sal están representados por la fórmula (3), donde R1 y R3 cada uno son átomo de hidrógeno o un grupo alquilo inferior; R2 y R4 cada uno son un grupo acilo, un grupo sililo alifático, un grupo aminoalquilo inferior que puede tener uno o más sustituyente(s) apropiado(s), un grupo heterocíclico que puede tener uno o más sustituyente(s) apropiado(s), o un grupo carboxi que puede estar esterificado por el residuo de celulosa opcionalmente sustituido por uno o más alquilos inferiores y/o alquenoilos inferiores; y R2 y/o R4 pueden estar reticulados en forma intramolecular y/o intermolecular con otro R2 o R4; R5 es un grupo perfluoroalquilo inferior que puede tener uno o más sustituyente(s) apropiado(s) o un grupo cicloalquilo sustituido por uno o más átomo(s) de flúor; n es un número entero de 1 ó más; y m es un número entero de 0, 1 ó más.Claim 1: A composition for preventing or treating hyperlipidemia, hypercholesterolemia or hyperglycemia, comprising a polymer or its salt, which can be obtained by polymerization of a monomer of formula (1) or its salt in the presence of a radical initiator, or by polymerization of a monomer of formula (1) or its salt with a monomer of formula (2) or its salt in a molar ratio of (1) :( 2) of 1: 0.1 to 1:25, in the presence of a radical initiator, where: R1 and R3 are each hydrogen atom or a lower alkyl group; R 2 and R 4 each are an acyl group, an aliphatic silyl group, a lower aminoalkyl group that may have one or more appropriate substituent (s), a heterocyclic group that may have one or more appropriate substituent (s) ), or a carboxy group esterified by the cellulose residue optionally substituted by one or more lower alkyls and / or lower alkenyl, as an active component, associated with a pharmaceutically acceptable non-toxic vehicle or excipient. Claim 6: The composition of claim 5, wherein the polymer or its salt is represented by the formula (3), wherein R1 and R3 are each hydrogen atom or a lower alkyl group; R 2 and R 4 each are an acyl group, an aliphatic silyl group, a lower aminoalkyl group that may have one or more appropriate substituent (s), a heterocyclic group that may have one or more appropriate substituent (s) ), or a carboxy group which may be esterified by the cellulose residue optionally substituted by one or more lower alkyls and / or lower alkenoyl; and R2 and / or R4 may be crosslinked intramolecularly and / or intermolecularly with another R2 or R4; R5 is a lower perfluoroalkyl group which may have one or more appropriate substituent (s) or a cycloalkyl group substituted by one or more fluorine atom (s); n is an integer of 1 or more; and m is an integer of 0, 1 or more.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPR767101 | 2001-09-13 | ||
| AU2002950181A AU2002950181A0 (en) | 2002-07-15 | 2002-07-15 | Composition for preventing or treating hyperlipemia, hypercholesterolemina or hyperglycemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR036512A1 true AR036512A1 (en) | 2004-09-15 |
Family
ID=25646799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020103462A AR036512A1 (en) | 2001-09-13 | 2002-09-12 | COMPOSITION TO PREVENT OR TREAT HYPERLIPIDEMIA OR HYPERGLUCEMIA USE AND TREATMENT METHOD |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR036512A1 (en) |
| AU (1) | AU2002326170A1 (en) |
| WO (1) | WO2003028739A2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5720103B2 (en) * | 2010-03-18 | 2015-05-20 | 東レ株式会社 | Silicone hydrogels, ophthalmic lenses and contact lenses |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5900475A (en) * | 1994-06-10 | 1999-05-04 | Geltex Pharmaceuticals, Inc. | Hydrophobic sequestrant for cholesterol depletion |
| AU4369499A (en) * | 1998-06-30 | 2000-01-17 | Aventis Research & Technologies Gmbh & Co. Kg | Novel method for producing cross-linked vinyl polymers based on quaternary ammonium groups exhibiting a bile acid adsorbent effect |
-
2002
- 2002-09-09 WO PCT/JP2002/009181 patent/WO2003028739A2/en not_active Application Discontinuation
- 2002-09-09 AU AU2002326170A patent/AU2002326170A1/en not_active Abandoned
- 2002-09-12 AR ARP020103462A patent/AR036512A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002326170A1 (en) | 2003-04-14 |
| WO2003028739A3 (en) | 2003-09-04 |
| WO2003028739A2 (en) | 2003-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200702493A1 (en) | CONNECTIONS AND METHODS OF TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | |
| AR042583A1 (en) | MACROLIDOS | |
| ES2075082T3 (en) | ISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF GLAUCOMA OR EYE HYPERTENSION. | |
| NO20060973L (en) | Pyridyl derivatives and their use as tempeutic agents | |
| JO2282B1 (en) | Oxazol derivatives | |
| ATE473974T1 (en) | PYRROLOPYRIDINE-2-CARBONIC ACIDS AS INHIBITORS OF GLYCOGEN PHOSPHORYLASE | |
| MX2009005185A (en) | Thiophene analogues for the treatment or prevention of flavivirus infections. | |
| ATE360631T1 (en) | AZABICYCLIC HETEROCYCLES AS MODULATORS OF THE CANNABINOID RECEPTOR | |
| AR063684A1 (en) | DERIVATIVES OF 4, 4´-BIFENILDIILBIS (1H-IMIDAZOL-5, 2-DIIL) AS INHIBITORS OF THE HEPATITIS C VIRUS, COMPOSITION THAT INCLUDES THEM AND ITS USE TO TREAT AN INFECTION WITH HCV. | |
| NO20045103L (en) | Benzofused heteroarylamide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions comprising the same and methods for their use | |
| ATE360630T1 (en) | AZABICYCLIC HETEROCYCLES AS MODULATORS OF THE CANNABINOID RECEPTOR | |
| HUP0203874A2 (en) | Substituted 4-(phenyl-n-alkyl)-piperazine and piperidine derivatives and their use modulators of dopamine neutransmission and pharmaceutical compositions as containing them | |
| GB0413087D0 (en) | Therapeutic compounds | |
| MXPA05006196A (en) | Compounds and methods for the treatment or prevention of flavivirus. | |
| WO2002009702A3 (en) | Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure | |
| MX2007006504A (en) | Malonamide derivatives as inhibitors of gamma-secretase for the treatment of alzheimer s disease. | |
| CA2380414A1 (en) | Method of cancer treatment | |
| ES2172415A1 (en) | Method for reducing intraocular pressure using indole derivatives | |
| NO20003773L (en) | Cyclobutene derivatives, their preparation and their therapeutic uses | |
| NZ506497A (en) | Indole derivatives, pharmaceuticals thereof and their use in lowering intraocular pressure or for the treatment or prevention of glaucoma or ocular hypertension | |
| CO5721014A2 (en) | POLYMERATION PROCESS TO PREPARE (CO) POLYMERS | |
| AR036512A1 (en) | COMPOSITION TO PREVENT OR TREAT HYPERLIPIDEMIA OR HYPERGLUCEMIA USE AND TREATMENT METHOD | |
| BR0315837A (en) | Heteroaryl hexanoic acid amide derivatives as immunomodulatory agents | |
| BR0311223A (en) | Method for the use of pyranindol derivatives to treat hepatitis C virus infection | |
| DE60104435D1 (en) | 2-thiocarbamoyloxy- und 2-carbamoyloxy-derivate von cyclopentyl-heptan(en)säure als therapeutische mittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |